We assign a fundamental rating of 4 out of 10 to BCRX. BCRX was compared to 524 industry peers in the Biotechnology industry. There are concerns on the financial health of BCRX while its profitability can be described as average. BCRX has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year BCRX has reported negative net income.
In the past year BCRX had a positive cash flow from operations.
In the past 5 years BCRX always reported negative net income.
BCRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BCRX has a better Return On Assets (-1.97%) than 87.60% of its industry peers.
BCRX has a better Return On Invested Capital (23.47%) than 98.28% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1.97%
ROE	N/A
ROIC	23.47%

ROA(3y)-35.62%

ROA(5y)-38.56%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BCRX has a better Operating Margin (12.69%) than 92.37% of its industry peers.
Looking at the Gross Margin, with a value of 97.39%, BCRX belongs to the top of the industry, outperforming 96.95% of the companies in the same industry.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.

		Industry Rank	Sector Rank
OM	12.69%
PM (TTM)	N/A
GM	97.39%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.65%

GM growth 5Y1.2%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BCRX is creating value.
Compared to 1 year ago, BCRX has more shares outstanding
The number of shares outstanding for BCRX has been increased compared to 5 years ago.
The debt/assets ratio for BCRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.15, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.15, BCRX is in line with its industry, outperforming 50.95% of the companies in the same industry.
BCRX has a debt to FCF ratio of 20.43. This is a negative value and a sign of low solvency as BCRX would need 20.43 years to pay back of all of its debts.
BCRX has a Debt to FCF ratio of 20.43. This is amongst the best in the industry. BCRX outperforms 90.08% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	20.43
Altman-Z	-2.15

ROIC/WACC2.99

WACC7.85%

2.3 Liquidity

BCRX has a Current Ratio of 1.87. This is a normal value and indicates that BCRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.87, BCRX is not doing good in the industry: 76.91% of the companies in the same industry are doing better.
A Quick Ratio of 1.83 indicates that BCRX should not have too much problems paying its short term obligations.
BCRX's Quick ratio of 1.83 is on the low side compared to the rest of the industry. BCRX is outperformed by 75.76% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.87
Quick Ratio	1.83

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.83%, which is quite impressive.
The Revenue has grown by 45.38% in the past year. This is a very strong growth!
Measured over the past years, BCRX shows a very strong growth in Revenue. The Revenue has been growing by 55.99% on average per year.

EPS 1Y (TTM)94.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%185.71%

Revenue 1Y (TTM)45.38%

Revenue growth 3Y42.06%

Revenue growth 5Y55.99%

Sales Q2Q%36.14%

3.2 Future

The Earnings Per Share is expected to grow by 41.76% on average over the next years. This is a very strong growth
BCRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.11% yearly.

EPS Next Y131.13%

EPS Next 2Y67.74%

EPS Next 3Y46.5%

EPS Next 5Y41.76%

Revenue Next Year37.72%

Revenue Next 2Y21.03%

Revenue Next 3Y17.7%

Revenue Next 5Y19.11%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 18.95, the valuation of BCRX can be described as rather expensive.
Based on the Price/Forward Earnings ratio, BCRX is valued cheaply inside the industry as 94.47% of the companies are valued more expensively.
BCRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.57, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	18.95

4.2 Price Multiples

BCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BCRX is cheaper than 94.08% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BCRX is valued cheaply inside the industry as 92.94% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	42.28
EV/EBITDA	22.2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 46.50% in the coming years.